Vietnam says Pfizer, MSD to grant its firms licenses to produce COVID pills
Hanoi: Drugmakers Pfizer Inc and MSD, known as Merck & Co Inc in North America, have agreed to give licenses to firms in Vietnam to produce COVID-19 treatment pills, Vietnam's ministry of health said on Friday.
The companies have sent letters of approval to the Drug Administration of Vietnam, the ministry said in a statement, for the production of Molnupiravir and Paxlovid pills.
Pfizer last week said it would allow generic manufacturers to supply its experimental antiviral COVID-19 pill to 95 low- and middle-income countries through a voluntary licensing agreement with international public health group Medicines Patent Pool (MPP).
Read also: Pfizer, Medicines Patent Pool ink pact to expand Covid-19 oral antiviral treatment access
Pfizer and MSD did not immediately respond to Reuters requests for comments.
The ministry said five local pharmaceutical companies have shown their interest in acquiring the license for producing Molnupiravir.
Vietnam has so far recorded 1.1 million COVID-19 infections and 24,000 deaths. Over 47% of its population of 98 million have been fully vaccinated against coronavirus.
The ministry said Vietnam has so far used 250,000 Molnupiravir doses, with 72%-93% of recipients recovering after five days.
Read also: Dr Reddys open to making Pfizer COVID pill after deal with Merck
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.